vs
NEKTAR THERAPEUTICS（NKTR）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
NEKTAR THERAPEUTICS的季度营收约是RIVERVIEW BANCORP INC的1.6倍（$21.8M vs $14.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -165.4%，领先175.2%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs -25.3%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-65.0M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs 0.4%）
内克塔医疗是一家美国生物制药企业，1990年成立，总部位于加利福尼亚州旧金山。该企业依托专有的聚乙二醇化技术与先进高分子偶联技术，通过改性物质化学结构研发候选新药，可改善药物滞留性、溶解度等特性，同时也是安进、默克、辉瑞等多家知名药企的技术供应商。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
NKTR vs RVSB — 直观对比
营收规模更大
NKTR
是对方的1.6倍
$14.0M
营收增速更快
RVSB
高出35.6%
-25.3%
净利率更高
RVSB
高出175.2%
-165.4%
自由现金流更多
RVSB
多$64.2M
$-65.0M
两年增速更快
RVSB
近两年复合增速
0.4%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $21.8M | $14.0M |
| 净利润 | $-36.1M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -126.9% | 12.4% |
| 净利率 | -165.4% | 9.8% |
| 营收同比 | -25.3% | 10.4% |
| 净利润同比 | -596.9% | 11.8% |
| 每股收益（稀释后） | $-4.67 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NKTRRVSB
| Q4 25 | $21.8M | $14.0M | ||
| Q3 25 | $11.8M | $13.6M | ||
| Q2 25 | $11.2M | $13.3M | ||
| Q1 25 | $10.5M | $12.9M | ||
| Q4 24 | $29.2M | $12.7M | ||
| Q3 24 | $24.1M | $12.8M | ||
| Q2 24 | $23.5M | $12.2M | ||
| Q1 24 | $21.6M | $9.0M |
净利润NKTRRVSB
| Q4 25 | $-36.1M | $1.4M | ||
| Q3 25 | $-35.5M | $1.1M | ||
| Q2 25 | $-41.6M | $1.2M | ||
| Q1 25 | $-50.9M | $1.1M | ||
| Q4 24 | $7.3M | $1.2M | ||
| Q3 24 | $-37.1M | $1.6M | ||
| Q2 24 | $-52.4M | $966.0K | ||
| Q1 24 | $-36.8M | $-3.0M |
毛利率NKTRRVSB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 72.7% | — | ||
| Q3 24 | 81.6% | — | ||
| Q2 24 | 58.5% | — | ||
| Q1 24 | 60.6% | — |
营业利润率NKTRRVSB
| Q4 25 | -126.9% | 12.4% | ||
| Q3 25 | -268.6% | 10.2% | ||
| Q2 25 | -324.2% | 11.7% | ||
| Q1 25 | -425.8% | 11.3% | ||
| Q4 24 | 49.2% | 12.4% | ||
| Q3 24 | -142.4% | 15.5% | ||
| Q2 24 | -211.9% | 10.0% | ||
| Q1 24 | -163.7% | -47.5% |
净利率NKTRRVSB
| Q4 25 | -165.4% | 9.8% | ||
| Q3 25 | -301.3% | 8.1% | ||
| Q2 25 | -372.2% | 9.2% | ||
| Q1 25 | -486.4% | 8.9% | ||
| Q4 24 | 24.9% | 9.7% | ||
| Q3 24 | -153.6% | 12.2% | ||
| Q2 24 | -222.9% | 7.9% | ||
| Q1 24 | -170.1% | -34.7% |
每股收益（稀释后）NKTRRVSB
| Q4 25 | $-4.67 | $0.07 | ||
| Q3 25 | $-1.87 | $0.05 | ||
| Q2 25 | $-2.95 | $0.06 | ||
| Q1 25 | $-0.24 | $0.05 | ||
| Q4 24 | $-2.07 | $0.06 | ||
| Q3 24 | $-2.66 | $0.07 | ||
| Q2 24 | $-3.76 | $0.05 | ||
| Q1 24 | $-0.19 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.1M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $89.8M | $164.2M |
| 总资产 | $280.4M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NKTRRVSB
| Q4 25 | $15.1M | $28.6M | ||
| Q3 25 | $41.0M | $32.8M | ||
| Q2 25 | $43.0M | $34.2M | ||
| Q1 25 | $38.9M | $29.4M | ||
| Q4 24 | $44.3M | $25.3M | ||
| Q3 24 | $30.1M | $31.0M | ||
| Q2 24 | $27.9M | $27.8M | ||
| Q1 24 | $48.6M | $23.6M |
股东权益NKTRRVSB
| Q4 25 | $89.8M | $164.2M | ||
| Q3 25 | $85.1M | $163.5M | ||
| Q2 25 | $-24.2M | $162.0M | ||
| Q1 25 | $13.7M | $160.0M | ||
| Q4 24 | $60.7M | $158.3M | ||
| Q3 24 | $48.9M | $160.8M | ||
| Q2 24 | $79.7M | $155.9M | ||
| Q1 24 | $126.7M | $155.6M |
总资产NKTRRVSB
| Q4 25 | $280.4M | $1.5B | ||
| Q3 25 | $301.3M | $1.5B | ||
| Q2 25 | $207.5M | $1.5B | ||
| Q1 25 | $256.2M | $1.5B | ||
| Q4 24 | $303.9M | $1.5B | ||
| Q3 24 | $308.0M | $1.5B | ||
| Q2 24 | $343.3M | $1.5B | ||
| Q1 24 | $396.0M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-65.0M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-65.0M | $-736.0K |
| 自由现金流率自由现金流/营收 | -298.0% | -5.2% |
| 资本支出强度资本支出/营收 | 0.1% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-208.7M | $20.4M |
8季度趋势，按日历期对齐
经营现金流NKTRRVSB
| Q4 25 | $-65.0M | $-506.0K | ||
| Q3 25 | $-48.8M | $16.8M | ||
| Q2 25 | $-45.7M | $-697.0K | ||
| Q1 25 | $-49.1M | $8.3M | ||
| Q4 24 | $-46.2M | $2.2M | ||
| Q3 24 | $-43.9M | $764.0K | ||
| Q2 24 | $-37.7M | $5.4M | ||
| Q1 24 | $-47.9M | $12.8M |
自由现金流NKTRRVSB
| Q4 25 | $-65.0M | $-736.0K | ||
| Q3 25 | $-48.9M | $16.4M | ||
| Q2 25 | $-45.8M | $-773.0K | ||
| Q1 25 | $-49.1M | $5.6M | ||
| Q4 24 | $-46.6M | $1.9M | ||
| Q3 24 | $-44.6M | $-1.4M | ||
| Q2 24 | $-37.9M | $5.3M | ||
| Q1 24 | $-48.0M | $7.1M |
自由现金流率NKTRRVSB
| Q4 25 | -298.0% | -5.2% | ||
| Q3 25 | -414.5% | 120.1% | ||
| Q2 25 | -409.6% | -5.8% | ||
| Q1 25 | -469.0% | 43.1% | ||
| Q4 24 | -159.9% | 15.0% | ||
| Q3 24 | -184.9% | -11.3% | ||
| Q2 24 | -161.3% | 43.7% | ||
| Q1 24 | -222.0% | 79.0% |
资本支出强度NKTRRVSB
| Q4 25 | 0.1% | 1.6% | ||
| Q3 25 | 1.0% | 2.9% | ||
| Q2 25 | 0.3% | 0.6% | ||
| Q1 25 | 0.0% | 21.0% | ||
| Q4 24 | 1.6% | 2.4% | ||
| Q3 24 | 2.8% | 17.3% | ||
| Q2 24 | 0.8% | 0.9% | ||
| Q1 24 | 0.7% | 62.0% |
现金转化率NKTRRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | -6.36× | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
